Immix Biopharma financials
$10.39−9.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$12.5M | -$10.8M | -$10.9M | -$7.7M | -$6.7M | -$4.7M | -$5.0M | -$7.4M | -$4.7M | -$5.6M | -$5.4M | -$4.5M |
| Net income | -$11.6M | -$10.0M | -$10.7M | -$7.6M | -$6.6M | -$4.5M | -$4.8M | -$7.1M | -$4.4M | -$5.3M | -$5.1M | -$4.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.18 | $-0.18 | $-0.27 | $-0.24 | $-0.22 | $-0.15 | $-0.15 | $-0.24 | $-0.15 | $-0.22 | $-0.23 | $-0.23 |
| EBITDA | -$12.4M | -$10.7M | -$10.8M | -$7.6M | -$6.7M | -$4.6M | -$5.0M | -$7.4M | -$4.7M | -$5.6M | -$5.4M | -$4.5M |
| Operating cash flow | -$11.7M | -$9.8M | -$11.0M | -$5.9M | -$5.3M | -$1.7M | -$1.5M | -$4.0M | -$5.3M | -$3.8M | -$2.7M | -$3.1M |
| Free cash flow | -$11.8M | -$9.9M | -$11.2M | -$6.3M | -$5.4M | -$1.8M | -$2.0M | -$4.3M | -$5.4M | -$4.1M | -$2.7M | -$3.1M |
| Diluted shares | 63.8M | 55.4M | 40.3M | 31.9M | 30.0M | 29.7M | 31.5M | 29.4M | 28.8M | 23.4M | 21.8M | 18.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.5M | $79.3M | $93.9M | $15.9M | $11.6M | $15.9M |
| Short-term investments | $6.6M | $11.3M | $6.5M | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $239.1M | $95.8M | $104.8M | $20.1M | $15.6M | $19.9M |
| Total liabilities | $10.2M | $11.5M | $11.0M | $11.8M | $11.0M | $10.3M |
| Shareholders' equity | $228.9M | $84.4M | $93.8M | $8.3M | $4.7M | $9.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology